Prof. Howard and his team (David and Yujin) presented their works at the 2025 American College of Clinical Pharmacology (ACCP) Annual Meeting, held in Phoenix, Arizona, from September 14–16, 2025. Under the theme “Leveraging Innovative Approaches to Transform Clinical Pharmacology,” the conference gathered experts to exchange insights on the evolving landscape in the field of clinical pharmacology.

The team delivered three poster presentations: 1) “Optimized In-Context Learning Outperforms Finetuning for Clinical Information Extraction across Diverse Healthcare Settings,” 2) “A Set of Inputs with Coverage Guarantee Enhances the Prediction of Drug Interactions,” and 3) “Constructing a Domain-Specific English–Korean Parallel Dictionary for Clinical Pharmacology and Regulatory Science Using a Large Language Model”. The presentations attracted considerable attention and prompted engaging exchanges among participants. The team’s research showed that in-context learning can serve as a data-efficient alternative to finetuning for clinical information extraction, offering practical guidance for applying large language models in healthcare settings with limited resources. They also demonstrated that incorporating input features with coverage guarantees, validated through conformal prediction, enhances the performance of LLM-based drug–drug interaction prediction. Lastly, the team showed that a domain-specific English–Korean parallel dictionary helps overcome language barriers and strengthens communication in clinical pharmacology and regulatory science.

As for the sessions in the ACCP conference, it began with a plenary session on optimizing patient outcomes through individualized pharmacotherapy. Subsequent symposia explored a wide range of critical topics, including diversity plans outlined by the U.S. Food and Drug Administration (FDA), therapeutic strategies for maternal and pediatric populations, innovations in dosing for preterm infants, therapeutic drug monitoring for biologics, and the application of artificial intelligence. Each meeting offered a clear picture of where clinical pharmacology is heading. The focus on individualized pharmacotherapy and model-informed drug development showed how artificial intelligence and mechanistic modeling are reshaping trial design and outcome prediction. At the same time, discussions on therapeutic drug monitoring for biologics and dosing in preterm infants revealed the field’s growing ability to tailor therapy for vulnerable populations.

Collectively, the conference underscored the expanding role of clinical pharmacology at the intersection of data science, patient diversity, and regulation. For the team, presenting at ACCP 2025 was not only an opportunity to share their own research but also a chance to situate their work within the broader trends shaping the field. The experience affirmed the value of their research trajectory and highlighted promising new directions for interdisciplinary and globally relevant contributions to clinical pharmacology.